TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18681815

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 150/12.5 mg (8 weeks)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 300/25 mg (8 weeks)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ (overall treatment)
Number of subjects: 370
Study: 16899803

Group type: EXPERIMENTAL
Intervention: Weight loss (WL) program; 1000 kcal/d energy deficit diet with exercise 3 d/wk; 10% weight loss goal
Number of subjects: 87

Group type: COMPARATOR
Intervention: Weight stable (WS) program; attended health information sessions
Number of subjects: 87
Study: 14514935

Group type: EXPERIMENTAL
Intervention: Self-management advice from the pharmacist with weekly telephone follow up for 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: No input from the pharmacist (Control)
Number of subjects: 24
Study: 10608914

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU or more per day)
Number of subjects: 0
Study: 9008978

Group type: EXPERIMENTAL
Intervention: Hot-dry environment (HD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hot-wet environment (HW)
Number of subjects: 8
Study: 1377830

Group type: EXPERIMENTAL
Intervention: CHART
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 41
Study: 6536506

Group type: COMPARATOR
Intervention: Postoperative continuous epidural morphine (group C)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oral phenoxybenzamine 10 mg (group D)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Postoperative mild analgesics (group B)
Number of subjects: 150
Study: 30641036

Group type: EXPERIMENTAL
Intervention: mTBI only group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All subjects with mTBI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medial prefrontal cortex connectivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posterior cingulate cortex connectivity
Number of subjects: 0
Study: 30272094

Group type: EXPERIMENTAL
Intervention: Multidomain intervention (MI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Omega-3 Polyunsaturated Fatty Acids supplementation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of MI and Omega-3 supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study: 27974006

Group type: EXPERIMENTAL
Intervention: Active therapeutic magnetic resonance (TMR) for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham application of TMR for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active therapeutic magnetic resonance (TMR) for 4 weeks (restricted to non-ischaemic patients, ABPI >0.8)
Number of subjects: 0
Study: 23627924

Group type: EXPERIMENTAL
Intervention: High-fibre bean-rich diet
Number of subjects: 173

Group type: COMPARATOR
Intervention: Low-carbohydrate diet
Number of subjects: 173
Study: 22373062

Group type: EXPERIMENTAL
Intervention: Instructor feedback (10 to 12 min, maximum of three times)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No instructor feedback (control group)
Number of subjects: 98
Study: 21097484

Group type: EXPERIMENTAL
Intervention: EMDEX II meter for measuring and recording magnetic fields
Number of subjects: 2148
Study: 17974883

Group type: EXPERIMENTAL
Intervention: Lyophilized bone chips with platelet gel (Group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lyophilized bone chips with platelet gel and bone marrow stromal cells (Group B)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Lyophilized bone chips without gel (Group C)
Number of subjects: 33
Study: 15870129

Group type: EXPERIMENTAL
Intervention: 250 microg r-hCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 500 microg r-hCG
Number of subjects: 60
Study: 12581547

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin QD 500 mg once daily for 3 days
Number of subjects: 891

Group type: COMPARATOR
Intervention: Ciprofloxacin BID 250 mg twice daily for 3 days
Number of subjects: 891
Study: 10208475

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlamydia pneumoniae infection
Number of subjects: 0
Study: 8665884

Group type: COMPARATOR
Intervention: Bupivacaine 5 mL
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 mL plus Thiomucase 10 U mL‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine 9 mL
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine 9 mL plus Thiomucase 10 U mL‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 2127828

Group type: EXPERIMENTAL
Intervention: Bicarbonate-based dialysis fluid
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acetate-based dialysis fluid
Number of subjects: 16
Study: 897173

Group type: EXPERIMENTAL
Intervention: Simethicone preparation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no simethicone preparation)
Number of subjects: 58
Study: 31917900

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 64
Study: 30506144

Group type: EXPERIMENTAL
Intervention: Cinacalcet (starting dose ≤ 0.20 mg/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 43
Study: 28456603

Group type: EXPERIMENTAL
Intervention: Lidocaine (2 mg kg−1) IV over 1 minute
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 41
Study: 25056999

Group type: EXPERIMENTAL
Intervention: Virtual reality-based intervention combined with conventional training (30 minutes each)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy (1 hour)
Number of subjects: 20
Study: 23792072

Group type: EXPERIMENTAL
Intervention: Migraine subjects during headache attack phases (ictal)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Migraine subjects during headache‐free phases (interictal)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 31
Study: 21315207

Group type: EXPERIMENTAL
Intervention: RB006 (pegnivacogin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg/kg RB006
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RB006
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin or low molecular heparin
Number of subjects: 0
Study: 19473505

Group type: EXPERIMENTAL
Intervention: Female sex workers (FSW)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Non-sex workers (non-SW)
Number of subjects: 506
Study: 16875447

Group type: EXPERIMENTAL
Intervention: Phototherapy (8 J/cm2 each day for five consecutive days using super luminous diodes with wavelengths of 880 and visible diodes of 660 nm)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham treatment (identical treatment from a dummy cluster)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study: 12894309

Group type: EXPERIMENTAL
Intervention: Laparoscopic abdominoperineal resection
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 28
Study: 10841242

Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency (RF) catheter ablation with internal saline irrigation
Number of subjects: 146
Study: 9410047

Group type: EXPERIMENTAL
Intervention: Dirithromycin (500 mg/day over 5 days)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Diacetylmidecamycin (600 mg, twice daily over 7 days)
Number of subjects: 174
Study: 1390171

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/g) applied twice daily
Number of subjects: 478

Group type: COMPARATOR
Intervention: Dithrocream (dithranol) applied for 30 min each day
Number of subjects: 478
Study: 4047707

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 400 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acetaminophen plus codeine, 300 mg plus 30 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30799926

Group type: EXPERIMENTAL
Intervention: Intensive risk factor intervention during the first year post-stroke
Number of subjects: 195

Group type: COMPARATOR
Intervention: Usual care during the first year post-stroke
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Both groups (ITT and CC populations)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards regression analysis
Number of subjects: 195
Study: 28960384

Group type: EXPERIMENTAL
Intervention: CBT-GSH + Noom
Number of subjects: 66

Group type: COMPARATOR
Intervention: CBT-GSH
Number of subjects: 66
Study: 27423320

Group type: EXPERIMENTAL
Intervention: Community based participatory research (CBPR) developed, multi‐level smoking cessation intervention with 1:1 community health worker contact, behavioral peer group sessions, and nicotine replacement for 24 weeks
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Community based participatory research (CBPR) developed, multi‐level smoking cessation intervention
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group received written cessation materials at weeks 1, 6, 12, 18
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Intervention participants who kept coach visits, attended group sessions, and used patches
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 409
Study: 24685561

Group type: EXPERIMENTAL
Intervention: $3 predictable amount
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Probabilistic amounts (50% chance of $6; 25% chance of $12; 12.5% chance of $24)
Number of subjects: 15

Group type: COMPARATOR
Intervention: $1 predictable amount
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10-mg cocaine units
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0-mg cocaine units
Number of subjects: 15
Study: 22066530

Group type: COMPARATOR
Intervention: Standard triple therapy (20 mg of rabeprazole, 1 g of amoxicillin, and 500 mg of clarithromycin, twice daily for 7 days)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Sequential therapy (5-day dual therapy: 20 mg of rabeprazole and 1 g of amoxicillin, twice daily, followed by 5-day triple therapy: 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily)
Number of subjects: 348
Study: 20440474

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Tension-free vaginal tape-obturator (TVT-O)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Both interventions (TVT and TVT-O)
Number of subjects: 267
Study: 17535291

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I)
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 747
Study: 15664680

Group type: EXPERIMENTAL
Intervention: Group ME (climbed up and down stairs)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group ES (practised electrostimulation)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group ME + ES (undertook both activities)
Number of subjects: 32
Study: 12127431

Group type: EXPERIMENTAL
Intervention: 150 mg lamivudine daily for 4 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 600 mg lamivudine daily for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Previous lamivudine treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Naive to lamivudine treatment
Number of subjects: 21
Study: 10198369

Group type: EXPERIMENTAL
Intervention: Subcutaneous IGF-I, 50 microgram/kg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 15
Study: 7786592

Group type: EXPERIMENTAL
Intervention: platinum-based combination chemotherapy with or without doxorubicin (DX)
Number of subjects: 129
Study: 1706741

Group type: EXPERIMENTAL
Intervention: Interferon 5 million units subcutaneously 3 times a week for 24 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 15
Study: 395854

Group type: EXPERIMENTAL
Intervention: Bupivacaine (mean dose 130 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pethidine (mean dose 183.3 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pethidine reversed by naloxone (200 micrograms intramuscularly)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 44
Study: 30248035

Group type: EXPERIMENTAL
Intervention: Core stabilization workouts
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine physical therapy
Number of subjects: 120
Study: 28733999

Group type: EXPERIMENTAL
Intervention: Retinyl propionate and climbazole (RPC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.1% retinol
Number of subjects: 45
Study: 26001561

Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate 100 mg
Number of subjects: 422

Group type: COMPARATOR
Intervention: Monthly intravenous ibandronate 1 mg
Number of subjects: 422
Study: 24113041

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d) plus Policosanol (20 mg/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Simvastatin (40 mg/d) plus Placebo (20 mg/d)
Number of subjects: 120
Study: 21840329

Group type: EXPERIMENTAL
Intervention: DHEA‐S 100mg/day for 3 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 19699113

Group type: EXPERIMENTAL
Intervention: 15% EDTA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10% EDTA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5% EDTA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% EDTA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coronal vs Apical thirds
Number of subjects: 40

Group type: COMPARATOR
Intervention: Different concentrations of EDTA
Number of subjects: 40
Study: 17873142

Group type: EXPERIMENTAL
Intervention: Oral nicorandil (15 mg/d) - Group A
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo - Group B
Number of subjects: 40
Study: 16287769

Group type: EXPERIMENTAL
Intervention: Computerized alerts and collaboration among healthcare professionals
Number of subjects: 400000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400000

Group type: EXPERIMENTAL
Intervention: Computerized alerts for amiodarone
Number of subjects: 400000

Group type: COMPARATOR
Intervention: Usual care for amiodarone
Number of subjects: 400000
Study: 12011520

Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine ethanol (CE group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 10% povidone‐iodine (PI group)
Number of subjects: 62
Study: 10216812

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg single dose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg repeated doses three times a day for six days and 60 mg on the seventh day)
Number of subjects: 14
Study: 7598923

Group type: EXPERIMENTAL
Intervention: Droperidol 0.5 mg with morphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Droperidol 1 mg with morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine (control group)
Number of subjects: 60
Study: 2366571

Group type: EXPERIMENTAL
Intervention: Fresh plasma
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fresh packed cell fraction
Number of subjects: 40
Study: 7352669

Group type: EXPERIMENTAL
Intervention: Midazolam maleate, 10 mg (95% confidence limits: 9-12 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam maleate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium thiopental, 200 mg
Number of subjects: 60
Study: 29806664

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study: 27692526

Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus 440 μg
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus 880 μg
Number of subjects: 347

Group type: COMPARATOR
Intervention: Intravitreal sirolimus 44 μg
Number of subjects: 347
Study: 24771163

Group type: EXPERIMENTAL
Intervention: Sleep apnea group (n=35 patients, 69 eyes)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (n=19 patients, 38 eyes)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 22468985

Group type: EXPERIMENTAL
Intervention: Multimodal, nondrug therapy (motor stimulation, activities of daily living, cognitive stimulation) for 6 months, 2 hours, 6 days a week
Number of subjects: 139

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 139
Study: 20589927

Group type: EXPERIMENTAL
Intervention: D-amphetamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18513418

Group type: EXPERIMENTAL
Intervention: Statistical methods for evaluating treatment effect from an RCT with a recurrent outcome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamma-Poisson model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independent-increment model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditional Cox model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marginal Cox model
Number of subjects: 0
Study: 15869766

Group type: EXPERIMENTAL
Intervention: Early-onset blind individuals (EB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sighted counterparts (SC)
Number of subjects: 0
Study: 12869856

Group type: EXPERIMENTAL
Intervention: Cimetidine (50 mg/hr) for 48 hours after aminophylline infusion
Number of subjects: 18
Study: 10500017

Group type: EXPERIMENTAL
Intervention: Tomato oleoresin (70-75 mg lycopene)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lycopene beadlets (70-75 mg lycopene)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tomato juice
Number of subjects: 15
Study: 7570895

Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of edrophonium and 3,4-diaminopyridine
Number of subjects: 0
Study: 1721516

Group type: EXPERIMENTAL
Intervention: Hypertonic saline prepared in hydroxyethylstarch solution (HS-HES, n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.5 solution (6% HES; n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 45
Study: 6160172

Group type: EXPERIMENTAL
Intervention: Ragweed antigen challenge
Number of subjects: 9
Study: 31775669

Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg) plus pessary
Number of subjects: 936

Group type: COMPARATOR
Intervention: Progesterone (200 mg) alone
Number of subjects: 936
Study: 28280973

Group type: EXPERIMENTAL
Intervention: Alkalosis normoxia (ALN)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Alkalosis hypoxia (ALH)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo normoxia (PLN)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo hypoxia (PLH)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pre-exercise alkalosis
Number of subjects: 11
Study: 25839715

Group type: EXPERIMENTAL
Intervention: TETRA 1.5 W/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TETRA 6.0 W/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 30
Study: 23377334

Group type: EXPERIMENTAL
Intervention: Calcipotriene plus betamethasone dipropionate
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Calcipotriene-only
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Vehicle-only
Number of subjects: 1152
Study: 20838771

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 1323
Study: 18950837

Group type: EXPERIMENTAL
Intervention: Thalidomide 300 mg daily for 24 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 46
Study: 16714251

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT), given orally.
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (without HRT)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 187
Study: 15607150

Group type: COMPARATOR
Intervention: HDRILBT alone (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HDRILBT with additional EBRT (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study: 11725694

Group type: EXPERIMENTAL
Intervention: DION (300 mg androstenedione, 150 mg dehydroepiandrosterone, 540 mg saw palmetto, 300 mg indole‐3‐carbinol, 625 mg chrysin, and 750 mg Tribulus terrestris per day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: DION
Number of subjects: 55
Study: 9298774

Group type: EXPERIMENTAL
Intervention: Swimming (SW)
Number of subjects: 11
Study: 7965657

Group type: EXPERIMENTAL
Intervention: 8-mg ondansetron tablet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 8-mg ondansetron tablet after a standard meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 8-mg ondansetron tablet with magnesium hydroxide/aluminum hydroxide antacid
Number of subjects: 36
Study: 2442936

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Etretinate
Number of subjects: 39
Study: 31900603

Group type: EXPERIMENTAL
Intervention: PF-06342674 (1, 3, 8 mg/kg/q2w or 6 mg/kg/q1w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30641142

Group type: EXPERIMENTAL
Intervention: YH4808 (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YH4808 (200 mg and 400 mg)
Number of subjects: 0
Study: 28606906

Group type: EXPERIMENTAL
Intervention: Intentional strategy (aggressive side branch protection strategy: elective two-stent strategy or jailed balloon technique)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Conventional strategy (provisional two-stent strategy or jailed wire technique)
Number of subjects: 566
Study: 26216250

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 0